Investors & Media

Ryvu Therapeutics has a track record of creating significant value for shareholders since its listing on the NewConnect market in 2011 and the subsequent IPO on the main market of Warsaw Stock Exchange in 2014. The company has delivered strong return on the combined $55M investment from private, public market investors, demonstrating research progress, bringing novel drug candidates to the clinic and additionally raising over $50M in non-dilutive grant funding to support its research efforts.

We value investor communications very highly and we build our investor relationships on trust and transparency. Ryvu is audited by EY and is subject to regulatory oversight of the Polish Financial Supervisory Authority, under the European Union and the Polish laws. Ryvu technological expertise is validated by global partnerships with Merck KGaA, Menarini Group and Leukemia & Lymphoma Society.

In 2016 Ryvu has spun out its NALP3 inflammasome assets to NodThera financed by Epidarex Venture Capital. In 2018 Sofinnova, 5AM Ventures, F-Prime and Epidarex have invested $40 M Series A in NodThera and Ryvu remains a shareholder in the company. For more information about NodThera see: www.nodthera.com.